Stemedica Cell Technologies, Inc. a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014.

Craig Carlson brings 34 years of financial, accounting, investor relations, and operational experience specifically in the biotech and biopharmaceutical industries to his role at Stemedica. Over the past 21 years of his career, Craig has played an integral role in raising over $420 million from private and public markets and has also had significant international experience having been responsible for various subsidiaries in China, Korea and the United Kingdom.

“Craig’s solid background in financial and accounting management along with his experience in SEC reporting, investor relations and in supporting financing initiatives in emerging growth companies is well-suited for Stemedica,” said Roger Howe, PhD, Stemedica’s Executive Chairman. “I have confidence that under Craig’s leadership, Stemedica will continue to improve our operating and financial efficiency and continue to create shareholder value.”

Previously, Craig was the Senior Vice President, Chief Financial Officer and Secretary at Talon Therapeutics, a specialty biopharmaceutical company, where he was responsible for all finance, accounting, SEC filings, information technology, and intellectual property with financial oversight on clinical trials. During his time at Talon he played an integral role in securing $100 million in financing; managed the Goldman Sachs mergers and acquisitions efforts; updated and streamlined Sarbanes Oxley controls and procedures; renegotiated licensing and royalty agreements, and actively participated in positioning the company for sale to Spectrum Pharmaceuticals in 2013.

He served a similar role as Senior Vice President, Chief Financial and Operating Officer as well as Managing Director U.K. for Cygnus Inc., a medical device company focused on manufacturing transdermal drug delivery systems and non-invasive glucose monitoring devices. At Cygnus, Craig supported the raise of more than $250 million from public and private markets as well as commercial partner payments. He also led the licensing negotiations for U.S. sales and distribution agreements as well as the national launch of the world’s first non-invasive glucose monitoring device. In addition, he initiated an aggressive investor relations marketing program that contributed to a tenfold increase in the company’s valuation. He also played a significant supporting role in the company’s sale of their transdermal patch business division to Johnson & Johnson.

During his tenure at Neurobiological Technologies, a biotech company focused on Phase III trials for Ischemic Stroke, he was instrumental in raising over $70 million in the midst of a difficult funding environment; successfully remedying two years of financial restatements from prior management; instituted new budgeting and cash flow forecasting systems; and led contract negotiations with CROs (Contract Research Organizations) and strategic partners.

Craig has an MBA from Stanford University Graduate School of Business, MS Ed. Counseling from Hofstra University and a BA in Political Science from Union College.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at